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Phage display screening identifies a novel
peptide to suppress ovarian cancer cells in
vitro and in vivo in mouse models
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Abstract
Background: Ovarian cancer is a possibly lethal gynecological malignancy and this study utilized phage display
technology to screen and identify peptides that specifically bind to ovarian cancer cells and explored the effects of
these peptides on ovarian cancer cells in vitro and in vivo.
Methods: The phage displayed peptide library was used to isolate the peptides binding to and internalizing into
the ovarian carcinoma cells. Positive phage clones were characterized with DNA sequencing and bioinformatics
analysis and then validated with immunofluorescence. Subsequently, the selected peptides were investigated for
their cancer-related functions, including cell adhesion, spreading, motility, and invasion in vitro and in vivo.
Results: Peptide1 read as SWQIGGNwas the positive peptide and showed preferential binding to the target cells.
Peptide 1 also inhibited cell proliferation, migration, invasion and adhesion of ovarian cancer HO8910 cells in vitro.
In vivo, Peptide 1 led to a lower tumorigenicity of HO8910 cells, which was characterized by the inhibitory effect on
tumor growth and metastasis of ovarian cells.
Conclusion: These studies demonstrate that the phage display-identified tumor cell-binding peptide was able to
control ovarian cancer cell viability, migration, invasion, and adhesion capacity in vitro as well as tumor growth and
metastasis in vivo. Future studies will be aimed at evaluating the clinical efficacy of the peptide SWQIGGN in ovarian
cancer patients.
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Background
Ovarian cancer is the most lethal gynecological malig-
nancy and is characterized by insidious onset, rapid pro-
gression and poor survival [1, 2]. Indeed, most of
ovarian cancer patients are diagnosed at an advanced
stage of the disease with evidence of metastasis spread-
ing beyond the ovaries [3] and the relapse rate of early
stage ovarian cancer is up to 40 % [4–7]. To date, the
treatment of ovarian cancer is much like those of all
other cancers and includes surgery, chemotherapy, radi-
ation therapy and immunotherapy [8]. If the tumor is
still confined in the ovary, surgery could be used to cure,
while, for decades, paclitaxel and carboplatin chemother-
apy have been used as the general standard of care for
most ovarian cancer patients. However, tumor resistance
does develop and certain subtypes of ovarian cancer are
insensitive to chemotherapy. Radiation therapy is not
effective for advanced stages of this disease and im-
munotherapy is just in the early stages of clinical trials
[9]. Therefore, the identification of novel targets is ur-
gently needed to develop innovative agents to effectively
control ovarian cancer metastasis and progression [10].
To this end, recent studies reported that the secretion of
cell surface proteins in human cancer cells could be
especially important as therapeutic targets [11–13]. Our
research is focused on identifying novel peptide-based
probes using combinatorial chemistry and bacteriophage
(phage) display to facilitate and identify novel cell
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surface molecules that could serve as biomarkers and
therapeutic targets. As phage display is a useful tech-
nique we are able to examine protein–protein, pro-
tein–peptide, and protein–DNA interactions [14–16].
The “displayed” (selected) peptide is used to identify
the receptor on the cell surface, which could be fur-
ther used as a diagnostic marker or therapeutic target
[14, 17]. Previous studies utilized phage display pep-
tide libraries to isolate and identify peptides that not
only specifically bind to cell receptors in a cell-
specific manner, but also exerted biological effects on
the target cells [18–21]. Thus, we aimed to screen
and identify peptides that could possess highly spe-
cific binding capabilities to human ovarian cancer
cells, and then to investigate the potential of these
selected peptides in terms of the control of ovarian
cancer in vitro and in vivo. We carried out a series of
experiments to explore whether such a peptide was
effective in controlling ovarian cancer growth in vitro
and in vivo. To the best of our knowledge, this study
is the first report of such an approach to identify
novel targets for ovarian cancer.
Methods
Cell lines and culture
A human ovarian cancer cell line, HO8910, was obtained
from the Laboratory Animal Center, Sun-Yatsen Univer-
sity, Guangdong, China, and grown in Roswell Park
Memorial Institute and cultured in 1640 medium (Invi-
trogen, Carlsbad, CA,, USA), supplemented with 10 %
fetal bovine serum (Hyclone, Logan, Utah, USA). The
human ovarian epithelial cell line OSE was obtained
from Xiandu Company (Guangzhou, China) and cul-
tured in serum-free DMEM-F12 medium (Invitrogen)
containing 10 mg/ml epidermal growth factor (Sigma, St
Louis, MO, USA) according to a previously reported
method [22]. These cells were incubated at 37 °C in a
humidified atmosphere with 5 % CO2.
Phage libraries and biopanning
The Ph.D.-c7c phage display peptide library was pur-
chased from New England Biolabs (Ipswich, MA, USA).
This library contained approximately 1 × 1013 pfu/mL
phages with a diversity of 1.28 × 109 unique peptide
sequences for up to 70 copies of each. Biopanning is an
affinity selection technique for identifying peptides that
bind to a given target [23]. In this study, the biopanning
began with the incubation of the phage display peptide
library with both normal and tumor cells, in which nor-
mal cells were used to deplete peptides that only bind to
normal cells and then further incubated with tumor cells
for identifying the peptides that only specifically bind to
tumor cells. Briefly, 1 ml of the primary phage display
peptide library (1 × 1011 pfu/ml) in 5 ml of phosphate
buffered saline (PBS) was added to the confluent cell
monolayer (normal ovarian epithelial cells, called deple-
tor) in a 60 mm diameter dish and the cells were then
incubated for 2 h on a rocker platform at 4 °C. After
that, the cell culture medium containing unbound phage
was collected and transferred to another cell monolayer
(HO8910 cells, called tester) and cells were incubated
for another 2 h at 4 °C. The cells were then intensively
washed four times with Tris-based saline (TBS)-0.2 %.
Tween-20 and cell-bound phages were eluted from the
cell surface by incubation with 1 mll of elution buffer
[0.2 M Glycine-HCL pH 2.2] for 10 min at 4 °C. The
elution was immediately neutralized by the addition of
150 ml of 1 M Tris–HCl buffer (pH 9.0) and the aliquot
of the eluted phage was used for microtitration, while
the remaining phage was subjected to the next rounds of
biopanning according to Wang JJ et al. [24]. for a total
of four rounds of in vitro biopanning. At the end of each
biopanning, the ratio of output vs. input phage numbers
(number of cell-associated phage divided by the num-
bers of total phage applied to the cells) was calculated
for each round.
Enzyme-linked immunosorbent assay (ELISA)
To identify phage clones, we performed an ELISA
assay. Briefly, after four rounds of in vitro biopan-
ning, twenty blue plaques were randomly chosen
from the titration plate. HO8910 cells were plated
into 96-well plates at a density of 104 cells/well,
washed and cultured in serum-free medium at 37 °C
for 1 h, and finally fixed in 4 % paraformaldehyde
for 20 min at room temperature. Cells were then
washed three times with PBS-Tween 20 (PBS with
0.05 % v/v Tween 20) and blocked with a blocking
buffer (PBST containing 3 % w/v BSA) for 1 h. The
selected phage clones (1010 pfu/well) and the nega-
tive control, M13KE phage (New England Biolabs)
were added individually onto the cells and further
incubated at 37 °C for 1 h. After that, the cells were
washed three times with PBST and then cultured for
1 h in the presence of the HRP-conjugated anti-M13
antibody (Abcam, Cambridge, UK) at a dilution of
1:20 in the blocking buffer. The cells were then
added to the Tetramethylbenzidine (TMB) working
substrate solution (50 μL/well; Sigma) and incubated
for 20 min at room temperature. The incubation was
stopped by adding 4 mol/L H2SO4. Finally, the ab-
sorbance was measured at 450 nm using a micro-
plate reader (Bio-Rad model 550, Hercules, CA).
Immunofluorescence staining
Immunofluorescence staining was performed as de-
scribed previously [25] to identify positive phage
clones that bind to the cell surface. Briefly, after the
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cells were incubated with phage clones for 1 h at
room temperature, the cells were washed with PBS
and incubated with M13 antibodies at a dilution of
1:300 (Abcam) for 1 h at room temperature, Cells
were subsequently washed with PBST and the second
antibodies M13-FITC (Abcam) were added and incu-
bated for 1 h at room temperature. The cells were
finally observed using an inverted microscope,
equipped with a digital camera and processed using
the Viewfinder program. For each experiment, normal
human ovarian epithelial cells were used as the nega-
tive control.
DNA sequencing and peptide synthesis
After four rounds of in vitro biopanning, twenty blue
plaques were randomly chosen from the titration plate
and amplified. Their ssDNA were extracted according to
the instruction manual (Bioteke, Beijing, China). DNA
sequencing analysis was performed by Shanghai Biotech-
nology (Shanghai, China) and the sequence data were
analyzed by using the BLAST and PMOTIF programs.
The candidate Peptide 1 (SWQIGGN, translated from
the selected M13 phage DNA sequence) and an irrele-
vant control peptide (QFHFDAP) were synthesized and
labeled with biotin by Shanghai Biotech Bioscience and
Technology (Shanghai, China).
Cell viability assay
The in vitro effects of the selected peptides on cells were
assessed using the MTT cell viability assay. Briefly, ovar-
ian cancer HO8910 cells were plated into 96-well plates
at a density of 104 cells/well, in triplicate and grown
overnight. The next day, 10 mM of synthetic peptides
were added into the cell culture wells at a final volume
of 200 ml of the regular growth medium/well. The ir-
relevant peptides were used as negative controls. At the
end of each time point of the experiment, the media was
removed and replaced with 20 ml of 5 mg/ml MTT
(3{4,5}-dimethylthia-zol-2,5-diphenyl tetrazolium brom-
ide (Sigma) in the growth medium, and the plates were
further incubated in standard conditions for 4 h. After-
wards, the supernatants of the cell culture were removed
and replaced with 150 ml dimethyl sulfoxide (DMSO) to
solubilize the MTT dye. Absorbance was then deter-
mined using a Spectra max 96-plate reader at 490 nm.
Ovarian cancer HO8910 cells, without any treatment,
were used as the blank group and DMSO was added to
the control wells at equal volumes to those used for the
test compounds.
Cell invasion and migration assays
The invasion and motility assays were performed using a
Transwell chamber with a 8-μm pore size polycarbonate
membrane (Corning, Hangzhou, China) as recommended
by the supplier. For the invasion assay, the upper
chamber of the polycarbonate filter was coated with
10 μl of Matrigel (New England Biolabs) at a dilution
of 1:3 with the growth medium. The chambers were
then incubated at 37 °C for 30 min to allow the Matrigel
to form a continuous thin layer. The Peptide 1-HO8910,
control peptide-HO8910, and HO8910 cells were starved
for 24 h and then harvested. 5× 104 cells in 200 μl of 0.5 %
bovine serum albumin (Sigma) were placed in the upper
chamber. The lower chamber was then filled with 600 μl
of growth medium subsidized with 20 % fetal bovine
serum. Cells were then cultured at 37 °C with 5 % CO2 for
48 h. Afterwards, cells on the upper surface of the filter
were removed using a cotton swab, whereas cells that
invaded through the Matrigel filter to the lower sur-
face were fixed with 4 % neutral-buffered formalin
and stained in 0.01 % crystal violet solution. The cell
numbers in five fields (up, down, median, left, and
right. ×200) were counted for each chamber, and the
results were expressed as the mean ± SD. The tumor
cell migration assay was performed in the same man-
ner, with the exception that the filter was not coated
with Matrigel.
Cell adhesion assay
To assess cell adhesion capacity after treatment with or
without the peptides, we performed a cell adhesion assay.
Briefly, the 96-well plate was first coated with 30 μl of
Matrigel at a dilution of 1:3 in PBS and incubated over-
night with 0.1 % BSA. Three groups of cells (the Peptide
1-HO8910, control peptide-HO8910, and HO8910 cells)
were washed three times in serum-free medium, resus-
pended at a concentration of 1 × 106 cells/ml in serum-
free medium and added into each well at 100 μl/well and
the cells were then incubated at 37 °C for 1 h. Unattached
cells were washed away with PBS. 10 μl of the MTT
solution was then added into each well and the plates
were further incubated for 4 h. 100 μl of DMSO was
added to replace the growth medium to dissolve for-
mazan by shaking for 10 min. Absorbance values (A)
were measured at a wavelength of 492 nm using a
microplate reader. Results were expressed as the
mean ± SD and the adhesion rate was calculated using
the formula: Relative adhesion rate (%) = (A492 of
Table 1 Specific enrichment of HO8910 cell-bound phages
using an initial input of 1011 pfu
Round Inputs (pfu/ml) Outputs (pfu/ml) Recovery rate (%)
1 2 × 1011 0.9 × 105 4.5 × 10−6
2 2 × 1011 3.4 × 106 1.7 × 10−5
3 2 × 1011 4.4 × 107 2.2 × 10−4
4 2 × 1011 2.2 × 108 1.1 × 10−3
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experimental group/A492 of control group) × 100 %.
Each experiment was repeated three times.
Animal studies
Twenty-one female athymic BALBC/c nude mice (4 to
6 weeks old with weights of 14.96 ± 0.96 g; animal ap-
proval number: 0113061) were obtained from Guangdong
Medical Laboratory Animal Center, Guangzhou, China
(SCXK(YUE)2008-0002) and maintained in Guangzhou
Medical College Laboratory Animal Center, and were kept
in specific pathogen free, temperature-controlled isolation
conditions, and fed with sterilized food and autoclaved
water. Animal breeding, care, and all experimental proce-
dures were approved by the ethical and humane commit-
tee of Guangzhou Medical College and carried out strictly
in accordance with the related regulations on administra-
tion of experimental animals under the SPF animal experi-
ment number: 0052246. Specifically, these 21 mice were
randomly divided into three groups: HO8910 cells pre-
incubated with Peptide 1, HO8910 cells pre-incubated
with the control peptide, and HO8910 cells without pre-
incubations. Cells were then injected into the enterocoelia
of each nude mouse with 1 × 106 cells in 200 ml volume.
The mice were then observed every two days and the
abdominal circumference was measured. On day 42,
the mice were euthanized and the tumors were dis-
sected after the abdominal circumference and ascitic
volume were measured. The tumor disseminated
localization and the number of individual dissemi-
nated tumors were counted and the inhibitory rate
was then calculated as follows: (control group average
tumor weight - the average tumor weight)/control
group average tumor weight] × 100 %. Tumor tissues
were assessed for histopathology, immunohistochemis-
try and apoptosis.
Immunohistochemistry
To detect expression of vascular endothelial growth fac-
tor (VEGF) in tumor tissues from animal experiments,
we performed immunohistochemistry using a rabbit
polyclonal anti-VEGF antibody (Sigma, St Louis, MO,
USA) according to the manufacturer’s instructions. The
anti-VEGF antibody was diluted to 1:100 and the bio-
tinylated goat anti-rabbit IgG was diluted to 1:200. The
staining results were evaluated by two independent
investigators who were unaware of the identity of the
tissue samples.
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay
TUNEL assay was used to detect apoptosis levels in
tumor tissues using an in situ cell death detection kit
conjugated with horseradish peroxidase (POD) (Roche
Applied Science, Indianapolis, IN, USA) according to
the manufacturer’s instructions. The rate of apoptosis
was evaluated by counting TUNEL-positive cells
(brown-stained) and the apoptotic index was defined as
the number of TUNEL-positive cells/total number of
cells in 5 randomly selected high-power fields (magnifi-
cation × 400).
Table 2 Peptide identified for HO8910 cell binding (Amino Acid
Sequences, deduced from DNA)
Clone Peptide sequence Incidence
Phage 1, 3, 7, 16, 19, and 20 SWQIGGN 6
Phage 4 QFHFDAP 1
Phage 6 TSPFVVP 1
Phage 8 TGNSNTQ 1
Phage15 TSHFEVP 1
Phage 9 and 10 IGNSNTL 2
Fig. 1 Efficacy of phage clones in binding to HO8910 versus normal ovarian cells. HO8910 cells and OSE were incubated with phage display
peptides. Unbound phages were removed by gentle washing and the bound phage clones were assayed by ELISA after incubation with HRP/
anti-M13 and then analyzed with a microplate reader at 450 nm. The mean OD values represent activity of phage binding to cells. M13KE and
PBS were used as controls. Lanes 1 to 12 depicts positive phage clones biopanned with HO8910 versus OSE cells
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Statistical analysis
Statistical analysis was performed with SPSS 13.0 statis-
tical software (SPSS Inc., Chicago, IL, USA). Results
were expressed as the mean ± SE of three or more obser-
vations (as indicated in each experiment). Differences
amongst the three groups were assessed using one-way
ANOVA and differences between the two groups were
assessed using the Student-Newman-Keuls (SNK). A p
value equal to or less than 0.05 was considered statisti-
cally significant.
Results and discussion
Identification of phage peptides that specifically bind to
the surface of ovarian cancer cells
In this study, we first screened and identified peptides
that could specifically bind to the cell surface of ovarian
cancer cells using the phage display assay. The input/
output phage ratio was calculated for each round of
HO8910 cell biopanning and the ratio gradually rose
and tended to stabilize after the fourth round. The data
showed that the number of the fourth round phages
Fig. 3 Effects of Peptide 1 on the regulation of HO8910 cell viability. Ovarian cancer cells were treated with Peptide 1, negative control peptide,
and blank control for up to 7 days and cell viability was assessed using a MTT assay. *P <0 .05
Fig. 2 Binding of Peptide 1 to the cell surface (×280). Immunofluorescence was used to stain Peptide 1 binding to HO8910 cells. Cells were
visualized using a Leica DMRA2 fluorescence microscope. a and b HO8910 cells. c and d OSE cells
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were 244 times higher than that of the first round ex-
periment (Table 1). After that, we performed ELISA to
confirm the cell binding affinity of twenty selected phage
clones. As shown in Fig. 1, 12 phage clones had very
high affinity to bind to HO8910 cells compared to that
of OSE cells. Thus, these 12 positive phage clones were
propagated and ssDNA was extracted for DNA sequen-
cing. After that, we identified unique DNA sequences
that contained seven amino acids (Table 2). After similar
peptide sequences had been aligned, most of the
sequences revealed a consensus sequence at their amino
terminal end and the peptide SWQIGGN appeared more
frequently and then the peptides were blasted using the
BLAST and PMOT IF programs to the Genbank data-
base. However, there was no homology to any known
protein that contained the phage peptide SWQIGGN,
and thus, we named this clone Peptide 1.
We subsequently performed immunochemistry tests
to further confirm the binding of Peptide 1 to the
HO8910 cells. As shown in Fig. 2, Peptide 1 was able to
Fig. 4 Effects of Peptide 1 on the regulation of ovarian cancer HO8910 cell metastatic phenotypes. a Matrigel invasion assay; b Transwell tumor cell
migration assay. The number of invading and migrating tumor cells was determined by counting the cells stained with 0.01 % crystal violet solution
in the lower side of Transwell filter. The decrease in the number of invading and migrating cells in Peptide 1-treated tumor cells compared to
those of the parental and negative control peptide cells (*P < 0.05). c and d represent quantitative data from a and b
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bind to HO8910 cells, but not normal human ovarian
epithelial cells. Moreover, the negative control peptide
clones did not significantly bind to both of the cell lines.
These data indicate that Peptide 1 (i.e., SWQIGGN) was
able to specifically bind to HO8910 cells.
Effects of selected Peptide 1 on the regulation of ovarian
cancer HO8910 cell biology in vitro
We then assessed the effect of Peptide 1 on the regulation
of ovarian cancer cell viability, apoptosis, invasion, and ad-
hesion in vitro. As shown in Fig. 3, there were no differ-
ences in cell viability among the three treated groups at day
1 and 2 (P > 0.05); however, between day 3 and 6, Peptide 1
significantly reduced ovarian cancer cell viability (p < 0.05),
but there were no differences in cell viability between the
VCSM13-HO8910 and the blank controls (p > 0.05).
Furthermore, the tumor cell Transwell migration and
invasion assay showed that HO8910-Peptide 1 had a
pronounced reduction in both cell migration and inva-
sion capacity compared to the negative peptide-treated
and blank control cells (p < 0.05), whereas the negative
peptide-treated and blank control cells showed similar
migration and invasion capacity (p > 0.05; Fig. 4). These
results indicated that Peptide 1 was able to block the
metastatic potential of HO8910 cells in vitro.
In addition, we also assessed the effect of Peptide 1 on
the regulation of HO8910 cell adhesion and found that
Peptide 1 significantly blocked HO8910 cell adhesion cap-
acity compared to the negative peptide-treated or bank
control cells (p < 0.05), whereas the negative peptide-
treated and blank control cells showed similar potential in
terms of adhesion capacity (p > 0.05; Fig. 5).
Effects of selected Peptide 1 on ovarian cancer HO8910
cells in vivo
To further investigate whether Peptide 1 can control ovar-
ian cancer in vivo, we treated ovarian cancer cells with
Peptide 1 or negative control peptides for five days and
then injected them into the enterocoelia of each nude
mouse. As shown in Fig. 6, the abdominal circumference
and mouse body weights were similar at the beginning of
the experiment, but the abdominal circumference of
HO8910-Peptide 1 cell-bearing mice didn’t show much
change two weeks after tumor cell injection, i.e., 65.8 ± 2.1
mm, whereas the abdominal circumference of mice bearing
HO8910-negative control peptide-treated and HO8910 par-
ental cells was 86.0 ± 3.4mm and 85.4 ± 4.2mm, respect-
ively (P < 0.05). As shown in Table 3, the volume of ascites,
the number of tumors, the total number of disseminated
tumor nodules and the tumor weight were all significantly
smaller in the Peptide 1 treated cell group than those of the
HO8910-negative control peptide and HO8910 parental
cell groups (p < 0.05). However, no statistical significance in
tumor growth was observed between control and HO8910
groups (p > 0.05). These results suggested that Peptide 1
was able to inhibit the growth and dissemination of ovarian
cancer cells in this mouse transplantation model.
Effects of Peptide 1 on the regulation of VEGF expression
and the apoptosis of ovarian cancer HO8910 cells in
transplanted tumor tissues in mice
To further assess the effects of Peptide 1 on ovarian can-
cer cells in vivo, we analyzed the expression of VEGF pro-
tein in ovarian cancer HO8910 cell transplanted tumor
tissues in mice. As shown in Fig. 7, immunohistochemical
Fig. 5 Effect of Peptide 1 treatment on regulation of ovarian cancer cell adhesion capability. Ovarian cancer cells were treated with Peptide 1,
negative control peptide, and blank control for five days and then the cells were seeded onto Matrigel-coated cell culture dishes and grown for
1 h. Cells were washed with PBS and the remaining cells were visualized using MTT staining and quantified. *P < 0.05 compared to the negative
control peptide-treated cells and blank cells; #P > 0.05 versus blank cells
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Fig. 6 Effect of Peptide 1 treatment on regulation of ovarian cancer cell growth in nude mice in an intraperitoneal tumorigenicity model. Comparison
of abdominal circumferences of three groups of nude mice. a1 Abdominal circumference in Peptide 1 group versus negative control peptide and
blank controls (p < 0.05). a2 Abdominal circumference growth curves of Peptide 1, negative control peptide, and blank control mice (*P < 0.05 from
this point onwards). b Comparison of tumor growth in three groups. Data are presented as mean ± SD. *P < 0.05 versus the negative control peptide
and Blank; #P >0.05 versus the Blank
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staining data showed that the expression of VEGF protein
in Peptide 1 treated ovarian cancer cells was markedly
lower than in the control HO8910 cell group (p < 0.05),
indicating that Peptide 1 could inhibit the expression of
VEGF in HO8910 cells in vivo.
Peptide 1 promoted cell apoptosis in vivo
We then performed the TUNEL assay to detect the
effect of Peptide 1 on the induction of cell apoptosis in
tissue specimens from the nude mouse intraperitoneal
tumorigenicity model. As shown in Fig. 8, the TUNEL-
positive nuclei were stained brown, and the apoptotic
index was significantly higher in the Peptide 1 group
compared to the control or HO8910 group (p < 0.05).
However, there was no statistical significance observed
between the control and HO8910 groups (P > 0.05).
These results indicated that Peptide 1 promoted cell
apoptosis in vivo.
Novel approaches could be used to identify and de-
velop more effective therapeutic agents for the control
of ovarian cancer in clinic. In this study, we utilized the
phage display technique to screen and identify peptides
that specifically bind to ovarian cancer cells to act as a
therapeutic strategy. We identified 12 phage clones that
could specifically bind to ovarian cancer cells but not
normal ovarian epithelial cells. After DNA sequencing
and blast search of Genbank, we found a novel peptide
SWQIGGN, which did not have an homology to any
known protein. We then confirmed its ability to bind to
ovarian cancer cells immunochemically and we explored
the effects of this peptide on the control of ovarian cancer
in vitro and in vivo. Our data showed that the treatment
of ovarian cancer cells with this peptide significantly
reduced tumor cell viability and suppressed tumor cell
migration, invasion, and adhesion capacity. In vivo nude
mouse studies showed that peptide treated-ovarian cancer
cells had much smaller ascite volume, a smaller number
of disseminated tumor nodules, and smaller tumor total
weights than those of negative control peptide-treated
HO8910 (P =0.0035) and parental HO8910 (P =0.0087)
cells. Treatment with this peptide also inhibited VEGF ex-
pression. Thus, our current data identified a phage
display-identified tumor cell-binding peptide that was able
to control ovarian cancer cell viability, migration, invasion,
adhesion capacity in vitro and tumor growth and metasta-
sis in vivo. Future studies are needed to evaluate its effi-
cacy and side effect profiles before it can be translated
into clinical applications for the treatment of ovarian
cancer patients.
The phage display technique is a useful tool to identify
short peptides or antibodies that can specifically bind to
and regulate functions of target proteins and the latter
could be used for early tumor diagnosis, vaccines and as
therapeutic targets. If proteins are expressed on the cell
Table 3 Effect of peptide 1 on malignant behaviors of ovarian cancer xenografts in nude mice
Group TFN MTF MR (%) TV (ml) TW (g) IR (%)
Blank 7 (7/7) 103 ± 26.40 100 1.40 ± 0.64 1.77 ± 0.44 _
Control 7 (7/7) 94.86 ± 30.62 100 1.32 ± 0.75 1.67 ± 0.37 5.65
Peptide 1 7 (5/7) 28.60 ± 13.16* 71.4* 0.24 ± 0.18# 0.52 ± 0.28* 70.62
TFN tumor formation number, MTF metastatic tumor foci, MR metastatic rate, TV tumor volume, TW tumor weight, IR inhibitory rate; The values of metastatic
tumor foci and tumor weight are presented as mean ± SD of n = 7 mice in relevant groups. *P < 0.001 and #p < 0.05 vs. the control and HO8910 groups
TFN, Five weeks post-inoculation, the nude mice were sacrificed, and then tumor formation was calculated for each mouse
MTF, collection of all tumors in each mouse, and then measurements of the number of tumors
MR, the MR of control = the MIF of control/ the MIF of blank; the MR of Peptide 1 = the MIF of Peptide 1 /the MIF of blank;
TW, collect all the tumors from each mouse, and then their weights by scale
IR, IR of control = [1-(the weight of control/the weight of blank)] *100 %
IR of Peptide 1 = [1-(the weight of Peptide 1/the weight of blank)] *100 %
Fig. 7 Effect of Peptide 1 treatment on regulation of VEGF expression in nude mice in an intraperitoneal tumorigenicity model (×400). Mouse tumor
tissues were dissected and immunostained with anti-VEGF antibody. Stained tissue sections were reviewed and scored (see Methods section). Expression
of VEGF in mouse tumor tissues of Peptide 1-treated tumor cells was markedly decreased compared to mouse tumor tissues of the negative control
peptide-treated tumor cells and parental HO8910 cells
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surface, they could also be useful for the delivery of bio-
active agents, such as small-molecule drugs and radionu-
cleotides to specifically target the cells which express
these proteins [26]. Recently, this technology was uti-
lized to screen prostate and breast cancer cell-specific
functional peptide ligands [27]. Our study identified a
group of ovarian cancer cell-specific binding peptides
and we chose one of these peptides for further study as
a therapeutic agent for ovarian cancer in vitro and in
vivo. The data demonstrated the usefulness of this tech-
nique to screen and identify tumor cell specific ligands.
In this study, we first biopanned our phage libraries
with normal ovarian epithelial cells in order to remove
the peptides that can bind to normal cells and then bio-
panned the remaining phage libraries with ovarian can-
cer cells to identify peptides that specifically bind to
ovarian cancer cells. We obtained the ratio of output to
input with an enrichment of 244 times in the last round
compared to the first round. This study differed from
that of other studies [28] in that they reported their data
by selected cell surface-bound peptides to specifically
bind to ovarian cancer cells but not stratified by normal
cells. After that, we selected 20 phage clones for con-
firmation and 12 of them were shown to specifically
bind to tumor cells versus normal cells. DNA sequen-
cing and a blast search of Genbank identified a novel
peptide SWQIGGN that didn’t show any homology to
any known protein. Thus, this peptide could be useful in
the control of ovarian cancer; therefore, we then
assessed the effects of this peptide on affecting the bio-
logical behaviors of ovarian cancer cells. The data
showed that this peptide was able to reduce tumor cell
viability, migration, invasion, and adhesion capacity.
However, to date, it is unclear how this peptide blocked
biological cell behavior. Future studies are needed to
identify the protein or cell structure that this peptide
binds to. However, since this peptide binds to a surface
protein on tumor cells, such a protein could be a cell
growth factor or hormone receptor and the binding of
this peptide blocks the ligands-binding to the protein
and therefore, inhibits their signaling transduction lead-
ing to the suppression of tumor cell growth, migration
and adhesion capacity. Negative controls (non-specific)
peptides used in the current study didn’t show much ac-
tivity in ovarian cancer cells. This negative control (i.e.,
IGNSNTL) was obtained after the fourth screening
(Table 2).
Moreover, cell motility and tumor cell invasion are
major components in the multistage process of cancer
metastasis [29, 30]. It is demonstrated that the in vivo
blockade of tumor cell spreading can suppress tumor
cell movement and invasiveness in vitro. Our current
data showed that this peptide inhibited ovarian cancer
cell adhesion, migration, and invasion capacity in vitro.
Fig. 8 Effect of Peptide 1 treatment on induction of apoptosis in a nude mouse intraperitoneal tumorigenicity model (×400). Mouse tumor tissues
were dissected and immunostained for TUNEL assay. Stained tissue sections were reviewed and scored (see Method section). a Representative images
of tumor sections examined by TUNEL assay. b The apoptotic index significantly increased in mouse tumor tissues of Peptide 1 group tumor sections
compared to those of the negative control peptide and parental group tumor sections. The data are presented as the average number of apoptotic
index ± SD. *P < 0.05 versus the negative control peptide and parental group; #P > 0.05 versus parental group
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Our nude mouse experiment results complimented our
in vitro data, showing that peptide-treated ovarian can-
cer cells had smaller tumor numbers and size, and
metastasis lesions in nude mice. At the gene level, this
peptide inhibited VEGF expression in tumor tissues.
Indeed, tumor angiogenesis is the key to facilitate tumor
growth and metastasis [2, 31]. However, it is unknown
whether this peptide did block tumor angiogenesis by
downregulation of VEGF expression. VEGF is the most
important vascular growth factor [31] and its expression
is regulated by different factors [32]. Thus, future studies
will be needed to explore how this peptide reduces
VEGF expression.
Conclusions
Our current study identified a novel peptide (SWQIGGN)
that can 1) specifically bind to ovarian cancer cells and 2)
control ovarian cancer in vitro and in vivo. However, our
current study is just proof-of-principle and more thorough
studies need to be performed before this peptide can be
used in a clinical setting. Our future studies will focus on:
1) understanding the underlying mechanism of its action
in ovarian cancer cells and identifying binding protein(s),
2) exploring the specificity of this peptide in other ovarian
cancer cell lines versus other types of cancer cells and 3)
assessing the clinical efficacy and side effects of this pep-
tide in ovarian cancer patients.
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